PMID- 19768728
OWN - NLM
STAT- MEDLINE
DCOM- 20100112
LR  - 20181201
IS  - 1531-8257 (Electronic)
IS  - 0885-3185 (Linking)
VI  - 24
IP  - 14
DP  - 2009 Oct 30
TI  - An open-label conversion study of pramipexole to ropinirole prolonged release in 
      Parkinson's disease.
PG  - 2121-7
LID - 10.1002/mds.22750 [doi]
AB  - Ropinirole prolonged release (PR) is a once daily oral dopamine agonist approved 
      for the treatment of Parkinson's disease (PD). The goal of this 4 week, 
      open-label study was to determine the most effective conversion ratio with the 
      fewest adverse effects (AEs) when switching from pramipexole to ropinirole PR. 
      Sixty patients with PD taking pramipexole were converted overnight to ropinirole 
      PR at ratios of 1:3, 1:4, or 1:5 such that 20 consecutive subjects were enrolled 
      in each group. Ropinirole PR dose adjustments were allowed to maintain efficacy 
      or to reduce AEs. An overnight switch from pramipexole to ropinirole PR was found 
      to be well tolerated and AEs were typical for a dopamine agonist. The most common 
      AEs were worsening of PD symptoms, dizziness, somnolence, and nausea, the 
      majority of which resolved after dose adjustments. Thirteen subjects discontinued 
      ropinirole PR before 4 weeks. These subjects were taking a significantly greater 
      dose of pramipexole, the majority greater than 4 mg/day, and tended to have 
      longer disease durations. A conversion ratio of 1 mg of pramipexole to 4 mg of 
      ropinirole PR resulted in the fewest discontinuations of ropinirole PR, the 
      fewest dose adjustments and the largest percentage of subjects that preferred 
      ropinirole PR.
CI  - (c) 2009 Movement Disorder Society.
FAU - Lyons, Kelly E
AU  - Lyons KE
AD  - Department of Neurology, Parkinson's Disease and Movement Disorder Center, 
      University of Kansas Medical Center, Kansas City, Kansas 66160, USA. 
      lyons.kelly@att.net
FAU - Pahwa, Rajesh
AU  - Pahwa R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mov Disord
JT  - Movement disorders : official journal of the Movement Disorder Society
JID - 8610688
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Benzothiazoles)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Indoles)
RN  - 030PYR8953 (ropinirole)
RN  - 83619PEU5T (Pramipexole)
SB  - IM
MH  - Accidental Falls
MH  - Aged
MH  - Antiparkinson Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Benzothiazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Cohort Studies
MH  - Dopamine Agonists/administration & dosage/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Dyskinesia, Drug-Induced/physiopathology
MH  - Female
MH  - Humans
MH  - Indoles/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/*drug therapy
MH  - Patient Satisfaction
MH  - Pramipexole
EDAT- 2009/09/22 06:00
MHDA- 2010/01/13 06:00
CRDT- 2009/09/22 06:00
PHST- 2009/09/22 06:00 [entrez]
PHST- 2009/09/22 06:00 [pubmed]
PHST- 2010/01/13 06:00 [medline]
AID - 10.1002/mds.22750 [doi]
PST - ppublish
SO  - Mov Disord. 2009 Oct 30;24(14):2121-7. doi: 10.1002/mds.22750.